PI-RADS v2.1与v2诊断性能及读者间一致性的系统综述与Meta分析
该系统综述与Meta分析纳入8项头对头研究(1836例患者,1921个病灶),比较PI-RADS v2.1与v2对临床显著前列腺癌(csPCa)的诊断性能。结果显示v2.1在全腺体及移行区的特异性显著低于v2,而敏感度、PPV、NPV无显著差异;读者间一致性均为中等至较好。结论认为v2.1诊断性能与v2相当,但特异性较低可能导致更多不必要的穿刺。
要点
- PI-RADS v2.1全腺体特异性显著低于v2(0.62 vs 0.66,p=0.02)。
- 移行区特异性v2.1亦显著低于v2(0.67 vs 0.72,p=0.01)。
- 敏感度、PPV、NPV及读者间一致性两版间无显著差异。
诊断标准与关键数值
- 全腺体汇总特异性:v2.1为0.62,v2为0.66(p=0.02);汇总敏感度、PPV、NPV无显著差异(p=0.17、0.31、0.41)。
- 移行区汇总特异性:v2.1为0.67,v2为0.72(p=0.01);汇总敏感度、PPV、NPV无显著差异(p=0.06、0.36、0.17)。
- 最高b值≥1400 s/mm²时,两版敏感度、特异性、PPV、NPV均无显著差异(p=0.52、0.4、0.5、0.47)。
- PI-RADS 1-2病灶csPCa汇总率:v2.1为6.6%,v2为7.3%(p=0.53);PI-RADS 3病灶:v2.1为24.1%,v2为26.8%(p=0.28)。
临床应用与阅片要点
- v2.1特异性较低,报告PI-RADS 3病灶时需注意可能增加阴性靶向穿刺率。
- 两版读者间一致性均为中等至较好,经验水平对v2.1诊断性能无显著影响。
局限性
- 纳入研究数量有限(8项),可能存在异质性。
- 未报告各研究的具体设备或序列细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To perform a systematic review and meta-analysis comparing diagnostic performance and inter reader agreement between PI-RADS v. 2.1 and PI-RADS v. 2 in the detection of clinically significant prostate cancer (csPCa).
METHODS: A systematic review was performed, searching the major biomedical databases (Medline, Embase, Scopus), using the keywords "PIRADS 2.1" or "PI RADS 2.1" or "PI-RADS 2.1". Studies reporting on head-to-head diagnostic comparison between PI-RADS v. 2.1 and v. 2 were included. Pooled sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were compared between PI-RADS v. 2.1 and v. 2. Summary receiver operator characteristic graphs were plotted. Analysis was performed for whole gland, and pre-planned subgroup analysis was performed by tumour location (whole gland vs transition zone (TZ)), high b-value DWI (b-value ≥1400 s/mm2), and reader experience (<5 years vs ≥5 years with prostate MRI interpretation). Inter-reader agreement and pooled rates of csPCa for PI-RADS 1-3 lesions were compared between PI-RADS v. 2.1 and v. 2. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies tool v. 2 (QUADAS-2).
RESULTS: Eight studies (1836 patients, 1921 lesions) were included. Pooled specificity for PI-RADS v. 2.1 was significantly lower than PI-RADS v. 2 for whole gland (0.62 vs 0.66, p = 0.02). Pooled sensitivities, PPVs and NPVs were not significantly different (p = 0.17, 0.31, 0.41). Pooled specificity for PI-RADS v. 2.1 was significantly lower than PI-RADS v. 2 for TZ only (0.67 vs 0.72, p = 0.01). Pooled sensitivities, PPVs and NPVs were not significantly different (p = 0.06, 0.36, 0.17). Amongst studies utilising diffusion-weighted imaging with highest b-value of ≥1400 s/mm2, pooled sensitivities, specificities, PPVs and NPVs were not significantly different (p = 0.52, 0.4, 0.5, 0.47). There were no significant differences in pooled sensitivities, specificities, PPVs and NPVs between PI-RADS v. 2.1 and PI-RADS v. 2 for less-experienced readers (p = 0.65, 0.37, 0.65, 0.81) and for more experienced readers (p = 0.57, 0.90, 0.91, 0.65). For PI-RADS v. 2.1 alone, there were no significant differences in pooled sensitivity, specificity, PPV and NPV between less and more experienced readers (p = 0.38, 0.70, 1, 0.48). Inter-reader agreement was moderate to substantial for both PI-RADS v. 2.1 and v. 2. There were no significant differences between pooled csPCa rates between PI-RADS v. 2.1 and v. 2 for PI-RADS 1-2 lesions (6.6% vs 7.3%, p = 0.53), or PI-RADS 3 lesions (24.1% vs 26.8%, p = 0.28).
CONCLUSIONS: Diagnostic performance and inter-reader agreement for PI-RADS v. 2.1 is comparable to PI-RADS v. 2, however the significantly lower specificity of PI-RADS v. 2.1 may result in increased number of unnecessary biopsies.
ADVANCES IN KNOWLEDGE: 1. Compared to PI-RADS v. 2, PI-RADS v. 2.1 has a non-significantly higher sensitivity but a significantly lower specificity for detection of clinically significant prostate cancer.2. PI-RADS v. 2.1 could potentially result in considerable increase in number of negative targeted biopsy rates for PI-RADS 3 lesions, which could have been potentially avoided.
引用
- Lee CH, Vellayappan B, Tan CH, et al. Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis. Br J Radiol. 2021. PMID: 34520694. doi:10.1259/bjr.20210509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。